PUBLICATION

The use of in vivo zebrafish assays in drug toxicity screening

Authors
Eimon, P.M., and Rubinstein, A.L.
ID
ZDB-PUB-090417-10
Date
2009
Source
Expert opinion on drug metabolism & toxicology   5(4): 393-401 (Review)
Registered Authors
Rubinstein, Amy
Keywords
none
MeSH Terms
  • Animals
  • Drug Evaluation, Preclinical/methods*
  • Drug Evaluation, Preclinical/standards*
  • Humans
  • Reproducibility of Results
  • Toxicity Tests/methods
  • Toxicity Tests/standards
  • Zebrafish*/physiology
PubMed
19368493 Full text @ Expert. Opin. Drug Metab. Toxicol.
Abstract
Anecdotal evidence has long suggested that zebrafish may be a good model to predict toxicity of human drugs. As summarized in this review, several groups have recently conducted systematic evaluations of zebrafish toxicity end points using large numbers of pharmacologically relevant compounds. Assays of particular interest include those for cardiotoxicity, ototoxicity, seizure liability, developmental toxicity and gastrointestinal motility. Results suggest that zebrafish assays can attain an acceptable level of predictivity, ranging from "sufficient" (65 - 75% predictivity) to "good" (75 - 85% predictivity) based on guidelines established for novel in vitro tests by the European Centre for the Validation of Alternative Methods. Further validation will probably be required to definitely establish zebrafish as a standard model for toxicity testing.
Genes / Markers
Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping